The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Is The Expected Market Size Of The Complicated Skin And Skin Structure Infections Drugs Market From 2026 To 2030?
The complicated skin and skin structure infections drugs market size has demonstrated robust growth in recent years. It is projected to expand from $10.36 billion in 2025 to $11.31 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.2%. The market’s historical growth can be attributed to a high incidence of bacterial skin infections, increasing awareness of healthcare-associated infections, a rise in hospital admissions due to CSSSI, the adoption of intravenous antibiotic therapy, and the widespread availability of generic antibiotics.
The complicated skin and skin structure infections drugs market size is projected to experience substantial growth over the next few years, expanding to $16.61 billion by 2030, at a compound annual growth rate (CAGR) of 10.1%. This expansion during the forecast period is attributable to the emergence of multidrug-resistant bacteria, advancements in targeted antibiotic therapies, the integration of digital health for infection management, an increasing demand for outpatient treatment options, and the expansion of biologics and novel antimicrobial agents. Significant trends anticipated for this period include a rising prevalence of antibiotic-resistant skin infections, the development of novel antibiotics for deep tissue infections, the adoption of advanced drug delivery systems, increasing hospitalization and outpatient care for csssi, and a focus on patient-centric therapeutic regimens.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12940&type=smp
Which Growth Drivers Are Contributing To The Progress Of The Complicated Skin And Skin Structure Infections Drugs Market?
A growing incidence of skin conditions is anticipated to fuel the expansion of the complicated skin and skin structure infections drugs market in the future. Skin ailments are health issues impacting the aesthetic, integrity, and performance of the skin. Such conditions may involve the skin, hair, nails, and associated tissues. A range of antibiotic medications is employed to combat resistant bacterial strains in cSSSI. Consequently, an increase in skin disease occurrences could result in new cSSSI drug approvals, enhance public awareness, and encourage prompt detection of complicated skin and skin structure infections. As an illustration, data from February 2023 by Cancer Research UK, a UK-based cancer research body, projects an annual increase in new melanoma skin cancer cases in the UK, rising from approximately 20,800 cases during 2023-2025 to around 26,500 cases by 2038-2040. This signifies an anticipated 9% surge in melanoma incidence rates, reaching 33 cases per 100,000 people annually by 2038-2040. Hence, the escalating occurrence of skin conditions propels the expansion of the complicated skin and skin structure infections drugs market.
Which Segments Are Included In The Analysis Of The Complicated Skin And Skin Structure Infections Drugs Market?
The complicated skin and skin structure infections drugs market covered in this report is segmented –
1) By Active Ingredients: Delafloxacin, Vancomycin, Ceftaroline Fosamil, Linezolid, Other Active Ingredients
2) By Route of Administration: Oral, Topical, Parenteral
3) By End User: Hospitals, Homecare, Specialty Clinics, Other End-Users
Subsegments:
1) By Delafloxacin: Delafloxacin Oral Tablets, Delafloxacin Injectable Form
2) By Vancomycin: Vancomycin Oral Solution, Vancomycin Injection
3) By Ceftaroline Fosamil: Ceftaroline Fosamil Injection
4) By Linezolid: Linezolid Oral Tablets, Linezolid Injectable Form
5) By Other Active Ingredients: Daptomycin, Tigecycline, Teicoplanin
Which Trends Are Impacting The Growth Of The Complicated Skin And Skin Structure Infections Drugs Market?
Leading firms within the complicated skin and skin structure infections drugs market are creating novel products, like dalbavancin, to secure a competitive advantage. Dalbavancin functions as a second-generation semi-synthetic lipoglycopeptide antibiotic, which interferes with bacterial cell wall production, thereby effectively eliminating gram-positive bacteria, such as methicillin-resistant Staphylococcus aureus (MRSA), rendering it effective for the treatment of acute bacterial skin and skin structure infections (ABSSSI). An example of this is AbbVie Inc., a pharmaceutical company based in the US, which disclosed in January 2023 that Xydalba (dalbavancin for injection) had received expanded approval for use in pediatric patients throughout Europe. Xydalba serves as an intravenous treatment prescribed for acute bacterial skin and skin structure infections in both adults and children aged three months and older. Its characteristics encompass a prolonged half-life that permits less frequent administration, powerful efficacy against resistant gram-positive pathogens, and a positive safety record, assisting clinicians in the efficient management of complex infections.
Which Key Industry Participants Are Active In The Complicated Skin And Skin Structure Infections Drugs Market?
Major companies operating in the complicated skin and skin structure infections drugs market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., GlaxoSmithKline plc, Cipla Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd, Fresenius Kabi, Macleods Pharmaceuticals, Sun Pharmaceutical Industries Limited, Dr Reddy’s Laboratories Ltd, Lupin Pharmaceuticals, Zydus Lifesciences Ltd., Glenmark Pharmaceuticals Ltd., Alkem Laboratories Limited, Wockhardt, Paratek Pharmaceuticals, Basilea Pharmaceutica AG, Melinta Therapeutics Inc., Nabriva Therapeutics AG, MerLion Pharmaceuticals GmbH
Read the full complicated skin and skin structure infections drugs market report here:
What Are The Leading Geographic Regions In The Complicated Skin And Skin Structure Infections Drugs Market?
Asia-Pacific was the largest region in the complicated skin and skin structure infections drugs market in 202. The regions covered in the complicated skin and skin structure infections drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Complicated Skin And Skin Structure Infections Drugs Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=12940&type=smp
Browse Through More Reports Similar to the Global Complicated Skin And Skin Structure Infections Drugs Market 2026, By The Business Research Company
Complicated Skin And Skin Structure Infections Drugs Market Report 2026
Acute Bacterial Skin And Skin Structure Infections Market Report 2026
Dermatology Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/dermatology-drugs-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model